NCT06424964 Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
| NCT ID | NCT06424964 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Belgian Research on AIDS and HIV Consortium |
| Condition | Human Immunodeficiency Virus |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2025-01-13 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV Secondary outcomes • Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis
Eligibility Criteria
Inclusion Criteria: * HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB/RPV between September 1, 2021, and March 31, 2024.
Contact & Investigator
Stéphane De Wit, MD/PhD
PRINCIPAL INVESTIGATOR
Belgian Research on AIDS & HIV Consortium
Frequently Asked Questions
Who can join the NCT06424964 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Human Immunodeficiency Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06424964 currently recruiting?
Yes, NCT06424964 is actively recruiting participants. Contact the research team at rakan.nasreddine@stpierre-bru.be for enrollment information.
Where is the NCT06424964 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06424964 clinical trial?
NCT06424964 is sponsored by Belgian Research on AIDS and HIV Consortium. The principal investigator is Stéphane De Wit, MD/PhD at Belgian Research on AIDS & HIV Consortium. The trial plans to enroll 600 participants.